Friday, April 13, 2012

  • Article

Supplemental Written Information Improves Prenatal Counseling: A Randomized Trial

 Author Affiliations
  1. aScott and White Healthcare, Temple, Texas and
  2. bMedical College of Wisconsin, Milwaukee, Wisconsin

Abstract

OBJECTIVE: To determine if maternal knowledge of prematurity is improved when verbal gestational age-specific counseling is supplemented with written gestational age-specific information.
METHODS: Prospective, randomized study of 60 pregnant participants assessed to be at risk for premature delivery between 23 and 34 weeks’ gestation. Counseling in the control group consisted of gestational age–specific verbal information, and counseling in the intervention group consisted of written gestational age–specific information 1 hour before the verbal gestational age–specific information. Both groups completed a Prematurity Knowledge Questionnaire after counseling and the State-Trait Anxiety Inventory before and after counseling. The Prematurity Knowledge Questionnaire consisted of questions regarding short-term problems (immature lungs, intraventricular hemorrhage, retinopathy, feeding problems, infection, apnea, and jaundice), long-term problems (chronic lung disease, postdischarge respiratory infections, visual impairment, hearing impairment, brain damage, and learning and behavior problems), and numerical outcome data (probabilities of survival, survival without significant morbidity, severe intraventricular hemorrhage, severe retinopathy, and chronic lung disease).
RESULTS: Knowledge of short-term problems was not statistically different between the intervention (82%) and control groups (67%). Knowledge of long-term problems was better in the intervention (71%) than the control group (45%). Knowledge of numerical data was better in the intervention (48%) than the control group (29%). State-Trait Anxiety Inventory scores decreased after counseling in the intervention group.
CONCLUSIONS: Supplementation of face-to-face verbal counseling with written information improved knowledge of long-term problems and knowledge of numerical outcome data, and it also decreased anxiety in women expecting a premature delivery.
Key Words:
  • Abbreviations:
    STAI —
    State-Trait Anxiety Inventory
    • Accepted January 5, 2012.

    Best Practices


    Best Practices for Health Care Professionals on the use of Polymerase Chain Reaction (PCR) for Diagnosing Pertussis



    With the continuing resurgence of pertussis, health care professionals will see more patients with suspected pertussis. Polymerase Chain Reaction (PCR) is an important tool for timely diagnosis of pertussis and is increasingly available to clinicians. PCR is a molecular technique used to detect DNA sequences of the Bordetella pertussis bacterium and unlike culture, does not require viable (live) bacteria present in the specimen. Despite these advantages, PCR can give results that are falsely-negative or falsely-positive. The following compilation of best practices is intended to help health care professionals optimize the use of PCR testing for pertussis by avoiding some of the more common pitfalls leading to inaccurate results.

    Testing Patients with Signs and Symptoms of Pertussis

    Early signs and symptoms of pertussis are often non-specific, making it difficult to determine clinically who has pertussis in the earliest stages.  However, only patients with signs and symptoms consistent with pertussis should be tested by PCR to confirm the diagnosis. Testing asymptomatic persons should be avoided as it increases the likelihood of obtaining falsely-positive results.  Asymptomatic close contacts of confirmed cases should not be tested and testing of contacts should not be used for post-exposure prophylaxis decisions.

    Optimal Timing for PCR Testing for Pertussis

    PCR has optimal sensitivity during the first 3 weeks of cough when bacterial DNA is still present in the nasopharynx.  After the fourth week of cough, the amount of bacterial DNA rapidly diminishes which increases the risk of obtaining falsely-negative results.  For more information, consult diagnostic testing for pertussis, including the use of serology for late diagnosis.
    PCR testing following antibiotic therapy also can result in falsely-negative findings. The exact duration of positivity following antibiotic use is not well understood, but PCR testing after 5 days of antibiotic use is unlikely to be of benefit and is generally not recommended.

    Optimal Specimen Collection for PCR Testing for Pertussis

    Specimens for PCR testing should be obtained by aspiration or swabbing the posterior nasopharynx.  Throat swabs and anterior nasal swabs have unacceptably low rates of DNA recovery and should not be used for pertussis diagnosis.  The swab tips may be polyester (such as Dacron®), rayon, or nylon-flocked.  Cotton-tipped or calcium alginate swabs are not acceptable as residues present in these materials inhibit PCR assays.  If feasible, nasopharyngeal (NP) aspirates that flush the posterior nasopharynx with a saline wash are preferred over swabs because this method results in a larger quantity of bacterial DNA in the sample.

    Avoiding Contamination of Clinical Specimens with Pertussis DNA

    Some pertussis vaccines[1] have been found to contain PCR-detectable B. pertussis DNA. Environmental sampling has identified B. pertussis DNA from these vaccines in clinic environments.  While the presence of this DNA in the vaccines does not impact the safety or immunogenicity of these vaccines, accidental transfer of the DNA from environmental surfaces to a clinical specimen can result in specimen contamination and falsely-positive results.  If health care professionals adhere to good practices, there is no need to switch vaccines.
    Preparation and administration of vaccines in areas separate from pertussis specimen collection areas may reduce the opportunity for cross contamination of clinical specimens.  Care should be taken when preparing and administering pertussis vaccines to avoid contamination of surfaces with vaccine.  General adherence to basic infection-control measures may further prevent contamination of specimens:
    • Wearing gloves immediately before and during specimen collection or vaccine preparation and administration with immediate disposal of gloves after the procedure, and
    • Cleaning clinic surfaces using a 10% bleach solution[2] to reduce the amount of nucleic acids in the clinic environment.
    The use of liquid transport media likely also contributes to falsely-positive results from contaminant DNA. When using liquid transport media, DNA that is accidentally transferred from hands to the swab shaft can be washed off into the liquid medium which freely circulates around the transport tube; this liquid is later extracted to obtain DNA for PCR testing. Use of a semisolid or non-liquid transport media or transport of a dry swab without media should prevent contaminant DNA on the swab shaft from reaching the part of the specimen that is later extracted. If using liquid transport medium, the swab stick should be handled with care and only above the red line or indentation which marks where the shaft is snapped off after insertion into the medium. Performing NP aspiration rather than swabbing the NP may also prevent contamination from occurring as the aspirate kit (syringe or bulb style) is a closed system at the point of specimen collection.

    Understanding and Interpreting Testing Results

    PCR assays for pertussis are not standardized across clinical laboratories.  Testing methods, DNA targets used and result interpretation criteria vary, and laboratories do not use the same cutoffs for determining a positive result.  With PCR, high cycle threshold (Ct) values indicate low levels of amplified DNA; for pertussis, these values may still indicate infection but can also be the result of specimens contaminated with DNA from the environment at the time of specimen collection.  Clinical laboratories might report high Ct values as any of the following:  positive, detected, indeterminate, or equivocal.  In addition, most clinical laboratories use a single target PCR for IS481, which is present in multiple copies in B. pertussis and in lesser quantities in B. holmesii and B. bronchiseptica.  Because this DNA sequence is present in multiple copies, IS481 is especially susceptible to falsely-positive results.  Use of multiple targets may improve specificity of PCR assays for pertussis.  Clinicians are encouraged to inquire about which PCR target or targets are used by their laboratories. Interpretation of PCR results, especially those with high Ct values, should be done in conjunction with an evaluation of signs and symptoms and available epidemiological information.

    Summary

    In summary, PCR is an important tool for diagnosis of pertussis especially in the setting of the current resurgence of pertussis disease. PCR can provide timely results with improved sensitivity over culture. Careful specimen collection and transport and a general understanding of the PCR assays performed will better ensure that clinicians obtain diagnostic test results that reliably inform patient diagnosis.

    Footnote

    1. Vaccines shown to contain PCR-detectable DNA include Pentacel®, Daptacel®, and Adacel®.  Leber A et al. Detection of Bordetella pertussis DNA in Acellular Vaccines and in Environmental Samples from Pediatric Physician Offices, in 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): Boston, USA.
    2. A 10% solution corresponds to 1 and a half cups of household bleach per gallon of water, or 1 part bleach to nine parts water.
    Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
    External Web Site Policy This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.
    Download page
    Red Book® Online News

    Check the Red Book Online News page often for breaking news related to pediatric infectious diseases and immunizations, including new vaccine recommendations, vaccine or antiviral shortages, product recalls, disease outbreaks, travel notices, and more. Red Book Online subscribers can also access the full news archives.

      Like AAP Red Book on Facebook

      March 2012

      Red Book Webinar: Human Papillomavirus Vaccines - Recommendations and UpdatesPosted 3/14/12
      Don�t miss April's Red Book webinar "Human Papillomavirus Vaccines: Recommendations and Updates" live on Thursday, April 12, 2012 from 1:00 - 2:00 PM ET.

      Joseph A. Bocchini, Jr, MD, FAAP, immediate past chair, AAP Committee on Infectious Diseases will discuss the latest recommendations and updates on HPV vaccines.

      Register today at www.aap.org/webinars/redbook.

      Erratum in 2012 Immunization SchedulesPosted 3/2/12
      The Centers for Disease Control and Prevention posted the following erratum in Morbid and Mortality Weekly Report for the Recommended Childhood and Adolescent Immunization Schedules�United States, 2012.

      The error is in the second bullet of footnote 1 in the Recommended immunization schedule for persons aged 0 through 6 years�United States, 2012. The text should read, �For infants born to hepatitis B surface antigen (HBsAg)�positive mothers, administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested for HBsAg and antibody to HBsAg (anti-HBs) 1 to 2 months after completion of at least 3 doses of the HepB series, at age 9 through 18 months (generally at the next well-child visit).�

      Please note that the Recommended Childhood and Adolescent Immunization Schedule for Persons 0 through 6 Years�United States, 2012 on Red Book Online was updated to reflect the correct information.


      February 2012

      Not Too Late for Flu VaccinePosted 2/28/12
      In a recent update on current influenza activity, the Centers for Disease Control and Prevention (CDC) stated that the influenza season is off to a very late start.

      The update summarized that influenza activity remains low in the US, but has recently increased. Influenza viruses have been reported from all 50 states this season; the viruses Influenza A, H3N2, 2009 Influenza A H1N1, and Influenza B have been identified in the US. All influenza virus strains are susceptible to the antiviral drugs Oseltamivir and Zanamivir.

      The CDC said that it is not too late to get the influenza vaccine and recommends that everyone 6 months of age and older, who has not already received the vaccine, do so.

      The full update can be viewed on the CDC website.

      AAP Publishes Revised Policy Statement on HPV Vaccine RecommendationsPosted 2/27/12
      Today, February 27, 2012, the American Academy of Pediatrics (AAP) pre-released a revised policy statement that includes recommendations for human papillomavirus (HPV) immunization of both males and females 11 through 12 years of age. This follows the October 25, 2011 Advisory Committee on Immunization Practices recommendation that males be vaccinated against HPV by receiving the quadrivalent HPV vaccine.

      The revised AAP policy statement is available on the Pediatrics website.

      Implementation guidance on supply, payment, coding, and liability issues is available on Red Book Online.

      2012 Immunization Schedules Now Available!Posted 2/1/12
      The annual recommended immunization schedules for children and adolescents in the United States for 2012 were approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, and the American Academy of Family Physicians. There are three immunization schedules, which can be viewed on Red Book Online: 0 to 6 years of age, 7 to 18 years of age, and a catch-up immunization schedule for those who start late or fall behind. Included are updated and clarified recommendations for the hepatitis B, influenza, Haemophilus influenzae type b, measles-mumps-rubella, hepatitis A, meningococcal, human papillomavirus, inactivated poliovirus, and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis adsorbed vaccines.

      2012 Immunization Schedules
      Recommended Immunization Schedule for Persons Aged 0 Through 6 Years�United States, 2012Recommended Immunization Schedule for Persons Aged 7 Through 18 Years�United States, 2012Catch-up Immunization Schedule for Persons Aged 4 Months Through 18 Years Who Start Late or Who Are More Than 1 Month Behind�United States, 2012


      January 2012

      Red Book Webinar: 2012 Immunization Schedule RecommendationsPosted 1/24/12
      Don�t miss February�s Red Book webinar, "2012 Immunization Schedule Recommendations," live on Thursday, February 2, 2012 at 1:00 PM ET. This webinar is eligible for CME (see details below).

      This 60-minute Red Book webinar will be led by H. Cody Meissner, MD, FAAP, Red Book Visual Library Associate Editor. Dr Meissner will discuss the new 2012 AAP/CDC/AAFP childhood immunization schedule and the basis for changes. The 2012 childhood immunization schedule is scheduled to publish in the February 2012 issue of Pediatrics. Objectives will include:
      • Review current guidance for HPV vaccine use in males
      • Discuss changes in meningococcal vaccine use for high risk as well as non-high risk children
      • Review changes in Tdap use in children 7 through 10 years of age, during pregnancy and in older adults
      • Summarize measles cases in 2011 and discuss the need for immunization of international travelers
      • Update influenza activity and vaccine use
      The webinar will be approximately 60 minutes (45 minutes for the presentation followed by a 15 minute Q&A period). Register today at www.aap.org/webinars/redbook

      The American Academy of Pediatrics (AAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
      The AAP designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
      This activity is acceptable for a maximum of 1.0 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
      The American Academy of Physician Assistants accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.
      This program is accredited for 1.0 NAPNAP CE contact hours of which 1.0 contain pharmacology (Rx) content per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.



      December 2011

      ACIP Recommends HPV Vaccine for MalesPosted 12/22/11
      On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended to the Centers for Disease Control and Prevention (CDC) that males be vaccinated against human papillomavirus (HPV) by receiving the quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co. Inc.).

      ACIP recommends that boys 11 or 12 years of age receive three doses of HPV4. ACIP also recommends vaccination with HPV4 for boys and young men aged 13 through 21 years who have not already received the vaccine or who have not completed the three-dose series. Males 22 through 26 years of age may also be vaccinated.

      These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males 9 through 26 years of age.

      The entire report can be read in Morbidity and Mortality Weekly Report (MMWR) on the CDC Web site.


      November 2011

      Neurologic Conditions and Immunosuppression Increase Risk of Mortality from pH1N1Posted 11/7/11
      According to a one-year multicenter study in the US, children with neurologic conditions and compromised immune function had an increased risk of mortality from the 2009 pandemic influenza A (pH1N1) virus. Coinfection with methicillin-resistant Staphylococcus aureus (MRSA) was a strong risk factor for mortality, increasing the risk of death in previously healthy children eight-fold.

      In the study, 838 children younger then 21 years of age who were admitted to 35 US pediatric intensive care units (PICU) were identified with confirmed or probable pH1N1. Only 49 of the patients had documentation of receiving influenza antiviral medications before being admitted into the PICU. Most of the patients (88.2%) received enteral oseltamivir in the PICU for a median of 4 days.

      Of these children, the median age was 6 years, 58% were male, and 70% had one or more chronic health conditions. Most had respiratory failure: 564 received mechanical ventilation; 162 received vasopressors; and 75 died. Preexisting neurologic conditions or immunosuppression, encephalitis, myocarditis, early presumed MRSA lung coinfection, and female gender were mortality risk factors.

      Since the 2009 pH1N1 continues to circulate worldwide, this article serves to remind pediatricians that better prevention and control of influenza is needed among children. Annual influenza vaccination of children 6 months of age and older is recommended by the American Academy of Pediatrics (AAP), the Advisory Committee on Immunization Practices, and Centers for Disease Control and Prevention.

      The full article can be read online in the AAP Pediatrics Digest.

      For additional information on pH1N1, visit the Influenza Resource Page


      October 2011

      AAP Re-emphasizes Use of PCV13Posted 10/21/11
      A recent data review by the Centers for Disease Control and Prevention (CDC) shows that children younger than 5 years of age continue to develop invasive pneumococcal disease (IPD) despite updated pneumococcal vaccination recommendations, prompting the agency to renew its call for appropriate immunization against Streptococcus pneumoniae infection. Because patients who only received the PCV7 vaccine remain at risk for IPD caused by serotypes unique to PCV13, health care professionals are reminded to:
      • Review the immunization history of all children 14 through 59 months of age who come to the office for any reason to determine if they are eligible for the supplemental dose of PCV13. If they have not received the supplemental dose, they should be immunized with PCV13.
      • Use only PCV13 vaccine. Any use of PCV7 vaccine should be discontinued even if the vaccine has not yet expired.
      The May 2010 American Academy of Pediatrics (AAP) policy statement �Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)� stated that PCV13 will replace PCV7 due to its expanded coverage over IPD.

      To view the entire policy statement, visit the AAP Policy page.

      For additional information on the use of PCV13, visit the article in AAP News.

      AAP Policy | AAP News
      Go to Red Book text:
      Section 3, Pneumococcal Infections


      September 2011

      Hepatitis A Vaccine Recommended for Contacts of International AdopteesPosted 9/27/11
      The AAP now recommends that household family members and close contacts of children adopted from countries with high rates of hepatitis A virus (HAV) be vaccinated. The new policy statement, "Recommendations for Administering Hepatitis A Vaccine to Contacts of International Adoptees," expands previous recommendations to only immunize travelers who are seeking to adopt children from countries with medium to high HAV infection rates. The new policy recommends routine administration of the vaccine for all household members and close contacts, including babysitters, during the 60-day period after the arrival of the adopted child. The first dose of the two-dose series should be given when the adoption is planned, ideally, two or more weeks before arrival. The second dose should be given at least six months after the first dose to provide long-term immunity from HAV infection.

      Recommendations for Administering Hepatitis A Vaccine to Contacts of International Adoptees
      Go to Red Book text:
      Section 3, Hepatitis A

      AAP Updates Tdap RecommendationsPosted 9/27/11
      Pertussis primarily affects adolescents and adults, but it can cause severe morbidity and death to young infants who are too young to be immunized. It is often transmitted by family members. In the policy statement, "Additional Recommendations for Use of Tetanus Toxoid, Reduced-Content Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap)," the AAP and the CDC revise previous recommendations for the use of the Tdap vaccine in children and adults. There is no longer any minimum interval between receiving a tetanus or diphtheria toxoid-containing vaccine and Tdap when given a short time apart. The AAP advises a single dose of Tdap should be administered to children 7 through 10 years of age who were underimmunized or who have an incomplete vaccine history. The AAP continues to recommend vaccination of adolescents, including pregnant adolescents. Pregnant women should also receive the vaccine. A single dose should be given to adults who have contact with infants, even if they are older than 65, and for health care workers of any age.

      Additional Recommendations for Use of Tetanus Toxoid, Reduced-Content Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap)
      Go to Red Book text:
      Section 3, Pertussis (Whooping Cough)

      AAP Updates Guidelines on Polio VaccinationPosted 9/27/11
      Despite significant progress in eliminating polio, wild poliovirus persists in a small number of Asian and African countries. It is essential to ensure high levels of immunity in US children to prevent outbreaks in case the virus is imported here. In the new policy statement, "Poliovirus," the AAP provides updated guidance on using several combination vaccines containing inactivated poliovirus vaccine, including the appropriate intervals between doses, immunization before travel to a country where polio is endemic, vaccination of immunocompromised children, and vaccination of adults at risk of exposure.

      Poliovirus
      Go to Red Book text:
      Section 3, Poliovirus Infections

      Use of Systemic and Topical Fluoroquinolones ExpandedPosted 9/27/11
      Appropriate prescribing practices for fluoroquinolones are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children becomes better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in the new AAP clinical report, "The Use of Systemic and Topical Fluoroquinolones." Although fluoroquinolones are reasonably safe in children, clinicians should be aware of the specific adverse reactions. Use of fluoroquinolones in children should continue to be limited to treatment of infections for which no safe and effective alternative exists.

      The Use of Systemic and Topical Fluoroquinolones
      Go to Red Book text:
      Section 4, Fluoroquinolones

      Updated AAP Varicella Policy StatementPosted 9/23/11
      The American Academy of Pediatrics (AAP) updated its statement on the prevention of varicella in 2007 and reaffirmed that statement in 2010. The purpose of this brief vaccine policy statement, �Prevention of Varicella: Update of Recommendations for Use of Quadrivalent and Monovalent Varicella Vaccines in Children,� is to provide additional data to update these recommendations.

      The routinely recommended ages for measles, mumps, rubella, and varicella vaccination continue to be 12 through 15 months for dose 1, and 4 through 6 years for dose 2. For the first dose administered at ages 12 through 47 months, the AAP recommends either measles-mumps-rubella (MMR) and varicella vaccines administered separately, or measles-mumps-rubella-varicella (MMRV) vaccination. Use of separate MMR and varicella vaccines averts the slight increase in risk of fever and febrile seizures after MMRV administration but at the cost of the pain associated with an extra injection and the risk of an infant falling behind schedule if all vaccines indicated at that visit are not given.

      For the first dose of measles, mumps, rubella, and varicella vaccines administered at ages 48 months and older, and for dose 2 at any age (15 months to 12 years), MMRV is generally preferred over separate injections of MMR and varicella vaccines. The risk of febrile seizures is not increased in older children who receive the second dose of MMRV.

      Prevention of Varicella: Update of Recommendations for Use of Quadrivalent and Monovalent Varicella Vaccines in Children
      Go to Red Book text:
      Section 3, Varicella-Zoster Infections

      AAP Early-Releases 2011-2012 Influenza PolicyPosted 9/2/11
      The American Academy of Pediatrics (AAP) has published its policy statement, "Recommendations for Prevention and Control of Influenza in Children, 2011-2012" as an early release on the Pediatrics website (it will also appear in the October print issue). The key points for the upcoming 2011–2012 season are that
      • the influenza vaccine composition for the 2011–2012 season is unchanged from the 2010–2011 season
      • annual universal influenza immunization is indicated
      • a simplified dosing algorithm for administration of influenza vaccine to children 6 months through 8 years of age has been created
      • most children presumed to have egg allergy can safely receive influenza vaccine in the office without need for an allergy consultation
      • an intradermal trivalent inactivated influenza vaccine has been licensed for the 2011–2012 season for use in people 18 through 64 years of age.

      On the Red Book Online Influenza Resource Page (www.aapredbook.org/flu), the AAP Committee on Infectious Diseases has compiled a comprehensive list of influenza resources to serve as a centralized point of reference for vaccine guidance, prevention, treatment, payment, policies, news, and other information pertaining to influenza for infants, children, adolescents, and young adults. Go to the Influenza Resource Page to see
      • Links to the new AAP policy and other influenza-related AAP policies
      • Print-friendly PDFs of the 2 key new algorithms from the 2011-2012 policy
      • AAP implementation guidance, including coding, for the 2011-2012 influenza season
      • Educational opportunities from the AAP on influenza, including Red Book Webinars and PediaLink Hot Topics
      • Links to recent AAP News articles about influenza
      • Links to current ACIP/CDC recommendations and materials

      The Red Book Online Influenza Resource Page is continually updated during the influenza season, so be sure to check it often.

      Note:  Some providers may have inquiries from parents about new wording in this year's 2011-2012 inactivated influenza vaccine VIS that states: “Young children who get inactivated flu vaccine and pneumococcal vaccine (PCV13) at the same time appear to be at increased risk for seizures caused by fever. Ask your doctor for more information.”
       
      The latest AAP policy statement addresses this, in part, by stating, "On the basis of current data, prophylactic use of antipyretics in TIV-immunized children is not indicated, and current AAP and Advisory Committee on Immunization Practices (ACIP) recommendations for administration of TIV in this age group are unchanged. Febrile seizures can occur anytime a child has a fever, but the typical child who has a febrile seizure quickly and fully recovers."
       
      More information is needed before any science-driven recommendation change can be made, so additional data will continue to be collected and analyzed this season. The AAP believes that ensuring both vaccines are given in a timely fashion outweighs any perceived benefit associated with giving them at separate times.

      Go to Red Book text:
      Section 3, Influenza
      Influenza Resource Page


      August 2011

      ACIP Recommendations for 2011�12 Influenza SeasonPosted 8/23/11
      The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention released updated guidance for the use of influenza vaccines in the United States for the 2011�12 influenza season. Influenza vaccine strains for the 2011�12 season are unchanged from those for the 2010�11 season. Vaccination of all persons 6 months of age and older continues to be recommended as does annual vaccination for those who received the vaccine for the previous season.

      See the full ACIP report for information regarding vaccine strains for the 2011�12 influenza season, the vaccination schedule for children 6 month through 8 years of age, and considerations for vaccination of persons with egg allergy.

      ACIP report
      Go to Red Book text:
      Section 3, Influenza
      Influenza Resource Page

      Red Book Now on Facebook!Posted 8/11/11
      The American Academy of Pediatrics Red Book now has its own page on Facebook. You can see the page at http://www.facebook.com/aapredbook or find it by searching on Facebook for "AAP Red Book."

      Join the Red Book community on Facebook today! A new way to keep track of Red Book informational updates, special events, infectious disease topics, and more.


      July 2011

      Correction to eAlert Message: Approval of New RotaTeq LabelPosted 7/26/11
      Please note a correction to the below message that was sent as a Red Book Online eAlert on Friday, July 22, 2011. The original message stated that the Centers for Disease Control and Prevention approved a new label for RotaTeq, which is incorrect. The message should state that the Food and Drug Administration (FDA) approved the new label for RotaTeq.

      Corrected message:
      The FDA approved a new label for RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent). The new label now contains a contraindication for history of intussusception. In addition, the Prescribing Information and Patient Package Insert were revised.

      Approval Letter
      Prescribing Information

      Go to Red Book text:
      Section 3, Rotavirus Infections

      Approval of New RotaTeq LabelPosted 7/22/11
      The Centers for Disease Control and Prevention approved a new label for RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent). The new label now contains a contraindication for history of intussusception. In addition, the Prescribing Information and Patient Package Insert were revised.

      Approval Letter
      Prescribing Information

      Go to Red Book text:
      Section 3, Rotavirus Infections

      Label Change for Tamiflu for Oral SuspensionPosted 7/20/11
      Tamiflu (oseltamivir phosphate) for oral suspension labels are being changed to reduce the likelihood of prescribing and dosing confusion which can lead to medication errors. These changes include:
      • Concentration change from 12 mg/mL to 6 mg/mL; this lower concentration is less likely to become frothy when shaken, which will allow a more accurate measurement
      • Change in the measurements of the oral dosing device from milligrams to milliliters
      • Change to the dosing table to include a column for the volume (mL) based on the new 6 mg/mL concentration
      • Revised container labels and carton packaging
      • Revised compounding instructions for pharmacies to prepare a 6 mg/mL oral suspension from Tamiflu capsules in an emergency situation only if the commercially manufactured Tamiflu for oral suspension is unavailable
      Genentech, the manufacturer of Tamiflu for oral suspension, has begun distributing the new 6 mg/mL product and instituted a voluntary return program for wholesale buyers, distributors, and pharmacies of the 12 mg/mL product. The 12 mg/mL will remain in the marketplace until current supplies expire.

      Healthcare professionals should be aware that both concentrations of Tamiflu for oral suspension will be on the market during the 2011-2012 influenza season. To avoid potential medication errors, prescribers should include the new concentration (6 mg/mL) and dose in milliliters on all prescriptions for Tamiflu for oral suspension.

      Go to MedWatch for the entire safety alert, including a link to the Drug Safety Communication.

      Go to Red Book text:
      Section 3, Influenza
      Section 4, Antiviral Drugs


      March 2011

      Red Book Online Approved for Internet Point of Care CMEPosted 3/29/11
      Red Book Online recently became an approved source that you can search through the new PediaLink Internet Point of Care Search CME activity.

      Look for the "Earn CME" link on any Red Book Online content page. Click this link to go to the AAP PediaLink Internet Point of Care Search where you can start earning CME credit by following four easy steps:
      1. Identify the clinical question that prompted your information search.
      2. Initiate and store your results from searching content in Red Book Online.
      3. Document the sources that were consulted once the search is complete.
      4. List the expected application to practice in order to claim credit.
      This CME activity is available to all AAP fellows as a free member benefit. If logged in as an individual on Red Book Online, you will automatically be logged in on the PediaLink site after clicking the �Earn CME� link. If you are not logged in as an individual, simply sign in on the PediaLink home page and click the "Internet Point of Care Search" tab in the top navigation.


      February 2011

      U.S. Supreme Court Upholds Vaccine Injury Compensation ProgramPosted 2/22/11
      The U.S. Supreme Court ruled today in Bruesewitz v. Wyeth, Inc. (No. 09-152, S. Ct.) to preserve the Vaccine Injury Compensation Program (VICP) that was established in the National Childhood Vaccine Injury Compensation Act of 1986.

      In a 6-2 decision, the Court upheld a recent ruling by the Third Circuit Court and supported the Academy�s position in the case, stating "The National Childhood Vaccine Injury Act preempts all design-defect claims against vaccine manufacturers brought by plaintiffs who seek compensation for injury or death caused by vaccine side effects." Justice Breyer issued a concurring opinion citing the Academy�s support for the retention of vaccine manufacturer tort liability.

      For a link to the amici curiae brief filed by AAP in the case in 2010, and a link to the full decision of the Supreme Court (including Justice Breyer�s opinion), please see the statement issued by the AAP on the February 22, 2011 decision.

      Go to Red Book text:
      Section 1, Vaccine Safety and Contraindications
      Section 1, Reporting of Adverse Events

      PCR Testing for Pertussis � Best PracticesPosted 2/18/11
      Due to the continuing pertussis resurgence, the Centers for Disease Control and Prevention (CDC) Health Alert Network (HAN) sent out a message on February 16, 2011 providing best practices for health care professionals on using polymerase chain reaction (PCR) tests for diagnosing pertussis. The best practices include who and when to test; how to obtain specimens; and how do to avoid contamination of clinical specimens with pertussis DNA, including best practices for preparing and administering vaccines and adhering to basic infection-control measures. Also included are recommendations for understanding and interpreting PCR results.

      Visit the CDC web site to view the best practices for using PCR tests to diagnose pertussis.

      CDC web site
      Go to Red Book text:
      Section 3, Pertussis (Whooping Cough)


    January 2011

    Recommended Changes for Tdap Vaccine UsePosted 1/11/11
    The American Academy of Pediatrics Committee on Infectious Diseases approved the following changes for the use of tetanus toxoid, reduced content diphtheria toxoid and pertussis antigen (Tdap) vaccine in children and adults that were recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.
    • Removal of a minimum interval between receipt of a tetanus- or diphtheria-toxoid-containing vaccine and Tdap when Tdap is otherwise indicated;
    • Administration of a single dose of Tdap to children 7 through 10 years of age with incomplete or unknown pertussis vaccine history;
    • Administration of a single dose of Tdap to persons 65 years of age or older who have or anticipate having close contact with an infant younger than 12 months of age (e.g., grandparents, child care providers, health care workers); and
    • Permission to administer a single dose of Tdap in place of Td to any person 65 years of age or older who has not received Tdap previously.
    For additional information on these new recommendations, please see the article published in the January edition of AAP News.

    Go to Red Book text:
    Section 3, Tetanus (Lockjaw)
    Section 3, Diphtheria
    Section 3, Pertussis (Whooping Cough)

    New Recommendations for MCV4 UsePosted 1/6/11
    The American Academy of Pediatrics Committee on Infectious Diseases approved the two new modifications for the use of quadrivalent meningococcal vaccines (MCV4, Menactra, and Menveo) recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention. These new recommendations will affect the 2011 immunization schedule.

    The first recommendation is the addition of a second dose (at least two months apart from the first) of MCV4 for immunocompromised children (complement deficiency, asplenia, HIV infection).

    The second recommendation is the addition of a routine booster of MCV4 for adolescents at 16 years of age (i.e., vaccinate at 11 through 12 years followed by a booster at 16 years).

    For additional information on these new recommendations, please see the article published in the January edition of AAP News.

    Go to Red Book text:
    Section 3, Meningococcal Infections

    Red Book

    ® Online News

    Check the Red Book Online News page often for breaking news related to pediatric infectious diseases and immunizations, including new vaccine recommendations, vaccine or antiviral shortages, product recalls, disease outbreaks, travel notices, and more. Red Book Online subscribers can also access the full news archives.

      Like AAP Red Book on Facebook

      March 2012

      Red Book Webinar: Human Papillomavirus Vaccines - Recommendations and UpdatesPosted 3/14/12
      Don�t miss April's Red Book webinar "Human Papillomavirus Vaccines: Recommendations and Updates" live on Thursday, April 12, 2012 from 1:00 - 2:00 PM ET.

      Joseph A. Bocchini, Jr, MD, FAAP, immediate past chair, AAP Committee on Infectious Diseases will discuss the latest recommendations and updates on HPV vaccines.

      Register today at www.aap.org/webinars/redbook.

      Erratum in 2012 Immunization SchedulesPosted 3/2/12
      The Centers for Disease Control and Prevention posted the following erratum in Morbid and Mortality Weekly Report for the Recommended Childhood and Adolescent Immunization Schedules�United States, 2012.

      The error is in the second bullet of footnote 1 in the Recommended immunization schedule for persons aged 0 through 6 years�United States, 2012. The text should read, �For infants born to hepatitis B surface antigen (HBsAg)�positive mothers, administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested for HBsAg and antibody to HBsAg (anti-HBs) 1 to 2 months after completion of at least 3 doses of the HepB series, at age 9 through 18 months (generally at the next well-child visit).�

      Please note that the Recommended Childhood and Adolescent Immunization Schedule for Persons 0 through 6 Years�United States, 2012 on Red Book Online was updated to reflect the correct information.


      February 2012

      Not Too Late for Flu VaccinePosted 2/28/12
      In a recent update on current influenza activity, the Centers for Disease Control and Prevention (CDC) stated that the influenza season is off to a very late start.

      The update summarized that influenza activity remains low in the US, but has recently increased. Influenza viruses have been reported from all 50 states this season; the viruses Influenza A, H3N2, 2009 Influenza A H1N1, and Influenza B have been identified in the US. All influenza virus strains are susceptible to the antiviral drugs Oseltamivir and Zanamivir.

      The CDC said that it is not too late to get the influenza vaccine and recommends that everyone 6 months of age and older, who has not already received the vaccine, do so.

      The full update can be viewed on the CDC website.

      AAP Publishes Revised Policy Statement on HPV Vaccine RecommendationsPosted 2/27/12
      Today, February 27, 2012, the American Academy of Pediatrics (AAP) pre-released a revised policy statement that includes recommendations for human papillomavirus (HPV) immunization of both males and females 11 through 12 years of age. This follows the October 25, 2011 Advisory Committee on Immunization Practices recommendation that males be vaccinated against HPV by receiving the quadrivalent HPV vaccine.

      The revised AAP policy statement is available on the Pediatrics website.

      Implementation guidance on supply, payment, coding, and liability issues is available on Red Book Online.

      2012 Immunization Schedules Now Available!Posted 2/1/12
      The annual recommended immunization schedules for children and adolescents in the United States for 2012 were approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, and the American Academy of Family Physicians. There are three immunization schedules, which can be viewed on Red Book Online: 0 to 6 years of age, 7 to 18 years of age, and a catch-up immunization schedule for those who start late or fall behind. Included are updated and clarified recommendations for the hepatitis B, influenza, Haemophilus influenzae type b, measles-mumps-rubella, hepatitis A, meningococcal, human papillomavirus, inactivated poliovirus, and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis adsorbed vaccines.

      2012 Immunization Schedules
      Recommended Immunization Schedule for Persons Aged 0 Through 6 Years�United States, 2012Recommended Immunization Schedule for Persons Aged 7 Through 18 Years�United States, 2012Catch-up Immunization Schedule for Persons Aged 4 Months Through 18 Years Who Start Late or Who Are More Than 1 Month Behind�United States, 2012


      January 2012

      Red Book Webinar: 2012 Immunization Schedule RecommendationsPosted 1/24/12
      Don�t miss February�s Red Book webinar, "2012 Immunization Schedule Recommendations," live on Thursday, February 2, 2012 at 1:00 PM ET. This webinar is eligible for CME (see details below).

      This 60-minute Red Book webinar will be led by H. Cody Meissner, MD, FAAP, Red Book Visual Library Associate Editor. Dr Meissner will discuss the new 2012 AAP/CDC/AAFP childhood immunization schedule and the basis for changes. The 2012 childhood immunization schedule is scheduled to publish in the February 2012 issue of Pediatrics. Objectives will include:
      • Review current guidance for HPV vaccine use in males
      • Discuss changes in meningococcal vaccine use for high risk as well as non-high risk children
      • Review changes in Tdap use in children 7 through 10 years of age, during pregnancy and in older adults
      • Summarize measles cases in 2011 and discuss the need for immunization of international travelers
      • Update influenza activity and vaccine use
      The webinar will be approximately 60 minutes (45 minutes for the presentation followed by a 15 minute Q&A period). Register today at www.aap.org/webinars/redbook

      The American Academy of Pediatrics (AAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
      The AAP designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
      This activity is acceptable for a maximum of 1.0 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
      The American Academy of Physician Assistants accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.
      This program is accredited for 1.0 NAPNAP CE contact hours of which 1.0 contain pharmacology (Rx) content per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.



      December 2011

      ACIP Recommends HPV Vaccine for MalesPosted 12/22/11
      On October 25, 2011, the Advisory Committee on Immunization Practices (ACIP) recommended to the Centers for Disease Control and Prevention (CDC) that males be vaccinated against human papillomavirus (HPV) by receiving the quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co. Inc.).

      ACIP recommends that boys 11 or 12 years of age receive three doses of HPV4. ACIP also recommends vaccination with HPV4 for boys and young men aged 13 through 21 years who have not already received the vaccine or who have not completed the three-dose series. Males 22 through 26 years of age may also be vaccinated.

      These recommendations replace the October 2009 ACIP guidance that HPV4 may be given to males 9 through 26 years of age.

      The entire report can be read in Morbidity and Mortality Weekly Report (MMWR) on the CDC Web site.


      November 2011

      Neurologic Conditions and Immunosuppression Increase Risk of Mortality from pH1N1Posted 11/7/11
      According to a one-year multicenter study in the US, children with neurologic conditions and compromised immune function had an increased risk of mortality from the 2009 pandemic influenza A (pH1N1) virus. Coinfection with methicillin-resistant Staphylococcus aureus (MRSA) was a strong risk factor for mortality, increasing the risk of death in previously healthy children eight-fold.

      In the study, 838 children younger then 21 years of age who were admitted to 35 US pediatric intensive care units (PICU) were identified with confirmed or probable pH1N1. Only 49 of the patients had documentation of receiving influenza antiviral medications before being admitted into the PICU. Most of the patients (88.2%) received enteral oseltamivir in the PICU for a median of 4 days.

      Of these children, the median age was 6 years, 58% were male, and 70% had one or more chronic health conditions. Most had respiratory failure: 564 received mechanical ventilation; 162 received vasopressors; and 75 died. Preexisting neurologic conditions or immunosuppression, encephalitis, myocarditis, early presumed MRSA lung coinfection, and female gender were mortality risk factors.

      Since the 2009 pH1N1 continues to circulate worldwide, this article serves to remind pediatricians that better prevention and control of influenza is needed among children. Annual influenza vaccination of children 6 months of age and older is recommended by the American Academy of Pediatrics (AAP), the Advisory Committee on Immunization Practices, and Centers for Disease Control and Prevention.

      The full article can be read online in the AAP Pediatrics Digest.

      For additional information on pH1N1, visit the Influenza Resource Page


      October 2011

      AAP Re-emphasizes Use of PCV13Posted 10/21/11
      A recent data review by the Centers for Disease Control and Prevention (CDC) shows that children younger than 5 years of age continue to develop invasive pneumococcal disease (IPD) despite updated pneumococcal vaccination recommendations, prompting the agency to renew its call for appropriate immunization against Streptococcus pneumoniae infection. Because patients who only received the PCV7 vaccine remain at risk for IPD caused by serotypes unique to PCV13, health care professionals are reminded to:
      • Review the immunization history of all children 14 through 59 months of age who come to the office for any reason to determine if they are eligible for the supplemental dose of PCV13. If they have not received the supplemental dose, they should be immunized with PCV13.
      • Use only PCV13 vaccine. Any use of PCV7 vaccine should be discontinued even if the vaccine has not yet expired.
      The May 2010 American Academy of Pediatrics (AAP) policy statement �Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)� stated that PCV13 will replace PCV7 due to its expanded coverage over IPD.

      To view the entire policy statement, visit the AAP Policy page.

      For additional information on the use of PCV13, visit the article in AAP News.

      AAP Policy | AAP News
      Go to Red Book text:
      Section 3, Pneumococcal Infections


      September 2011

      Hepatitis A Vaccine Recommended for Contacts of International AdopteesPosted 9/27/11
      The AAP now recommends that household family members and close contacts of children adopted from countries with high rates of hepatitis A virus (HAV) be vaccinated. The new policy statement, "Recommendations for Administering Hepatitis A Vaccine to Contacts of International Adoptees," expands previous recommendations to only immunize travelers who are seeking to adopt children from countries with medium to high HAV infection rates. The new policy recommends routine administration of the vaccine for all household members and close contacts, including babysitters, during the 60-day period after the arrival of the adopted child. The first dose of the two-dose series should be given when the adoption is planned, ideally, two or more weeks before arrival. The second dose should be given at least six months after the first dose to provide long-term immunity from HAV infection.

      Recommendations for Administering Hepatitis A Vaccine to Contacts of International Adoptees
      Go to Red Book text:
      Section 3, Hepatitis A

      AAP Updates Tdap RecommendationsPosted 9/27/11
      Pertussis primarily affects adolescents and adults, but it can cause severe morbidity and death to young infants who are too young to be immunized. It is often transmitted by family members. In the policy statement, "Additional Recommendations for Use of Tetanus Toxoid, Reduced-Content Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap)," the AAP and the CDC revise previous recommendations for the use of the Tdap vaccine in children and adults. There is no longer any minimum interval between receiving a tetanus or diphtheria toxoid-containing vaccine and Tdap when given a short time apart. The AAP advises a single dose of Tdap should be administered to children 7 through 10 years of age who were underimmunized or who have an incomplete vaccine history. The AAP continues to recommend vaccination of adolescents, including pregnant adolescents. Pregnant women should also receive the vaccine. A single dose should be given to adults who have contact with infants, even if they are older than 65, and for health care workers of any age.

      Additional Recommendations for Use of Tetanus Toxoid, Reduced-Content Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap)
      Go to Red Book text:
      Section 3, Pertussis (Whooping Cough)

      AAP Updates Guidelines on Polio VaccinationPosted 9/27/11
      Despite significant progress in eliminating polio, wild poliovirus persists in a small number of Asian and African countries. It is essential to ensure high levels of immunity in US children to prevent outbreaks in case the virus is imported here. In the new policy statement, "Poliovirus," the AAP provides updated guidance on using several combination vaccines containing inactivated poliovirus vaccine, including the appropriate intervals between doses, immunization before travel to a country where polio is endemic, vaccination of immunocompromised children, and vaccination of adults at risk of exposure.

      Poliovirus
      Go to Red Book text:
      Section 3, Poliovirus Infections

      Use of Systemic and Topical Fluoroquinolones ExpandedPosted 9/27/11
      Appropriate prescribing practices for fluoroquinolones are essential as evolving resistance patterns are considered, additional treatment indications are identified, and the toxicity profile of fluoroquinolones in children becomes better defined. Earlier recommendations for systemic therapy remain; expanded uses of fluoroquinolones for the treatment of certain infections are outlined in the new AAP clinical report, "The Use of Systemic and Topical Fluoroquinolones." Although fluoroquinolones are reasonably safe in children, clinicians should be aware of the specific adverse reactions. Use of fluoroquinolones in children should continue to be limited to treatment of infections for which no safe and effective alternative exists.

      The Use of Systemic and Topical Fluoroquinolones
      Go to Red Book text:
      Section 4, Fluoroquinolones

      Updated AAP Varicella Policy StatementPosted 9/23/11
      The American Academy of Pediatrics (AAP) updated its statement on the prevention of varicella in 2007 and reaffirmed that statement in 2010. The purpose of this brief vaccine policy statement, �Prevention of Varicella: Update of Recommendations for Use of Quadrivalent and Monovalent Varicella Vaccines in Children,� is to provide additional data to update these recommendations.

      The routinely recommended ages for measles, mumps, rubella, and varicella vaccination continue to be 12 through 15 months for dose 1, and 4 through 6 years for dose 2. For the first dose administered at ages 12 through 47 months, the AAP recommends either measles-mumps-rubella (MMR) and varicella vaccines administered separately, or measles-mumps-rubella-varicella (MMRV) vaccination. Use of separate MMR and varicella vaccines averts the slight increase in risk of fever and febrile seizures after MMRV administration but at the cost of the pain associated with an extra injection and the risk of an infant falling behind schedule if all vaccines indicated at that visit are not given.

      For the first dose of measles, mumps, rubella, and varicella vaccines administered at ages 48 months and older, and for dose 2 at any age (15 months to 12 years), MMRV is generally preferred over separate injections of MMR and varicella vaccines. The risk of febrile seizures is not increased in older children who receive the second dose of MMRV.

      Prevention of Varicella: Update of Recommendations for Use of Quadrivalent and Monovalent Varicella Vaccines in Children
      Go to Red Book text:
      Section 3, Varicella-Zoster Infections

      AAP Early-Releases 2011-2012 Influenza PolicyPosted 9/2/11
      The American Academy of Pediatrics (AAP) has published its policy statement, "Recommendations for Prevention and Control of Influenza in Children, 2011-2012" as an early release on the Pediatrics website (it will also appear in the October print issue). The key points for the upcoming 2011–2012 season are that
      • the influenza vaccine composition for the 2011–2012 season is unchanged from the 2010–2011 season
      • annual universal influenza immunization is indicated
      • a simplified dosing algorithm for administration of influenza vaccine to children 6 months through 8 years of age has been created
      • most children presumed to have egg allergy can safely receive influenza vaccine in the office without need for an allergy consultation
      • an intradermal trivalent inactivated influenza vaccine has been licensed for the 2011–2012 season for use in people 18 through 64 years of age.

      On the Red Book Online Influenza Resource Page (www.aapredbook.org/flu), the AAP Committee on Infectious Diseases has compiled a comprehensive list of influenza resources to serve as a centralized point of reference for vaccine guidance, prevention, treatment, payment, policies, news, and other information pertaining to influenza for infants, children, adolescents, and young adults. Go to the Influenza Resource Page to see
      • Links to the new AAP policy and other influenza-related AAP policies
      • Print-friendly PDFs of the 2 key new algorithms from the 2011-2012 policy
      • AAP implementation guidance, including coding, for the 2011-2012 influenza season
      • Educational opportunities from the AAP on influenza, including Red Book Webinars and PediaLink Hot Topics
      • Links to recent AAP News articles about influenza
      • Links to current ACIP/CDC recommendations and materials

      The Red Book Online Influenza Resource Page is continually updated during the influenza season, so be sure to check it often.

      Note:  Some providers may have inquiries from parents about new wording in this year's 2011-2012 inactivated influenza vaccine VIS that states: “Young children who get inactivated flu vaccine and pneumococcal vaccine (PCV13) at the same time appear to be at increased risk for seizures caused by fever. Ask your doctor for more information.”
       
      The latest AAP policy statement addresses this, in part, by stating, "On the basis of current data, prophylactic use of antipyretics in TIV-immunized children is not indicated, and current AAP and Advisory Committee on Immunization Practices (ACIP) recommendations for administration of TIV in this age group are unchanged. Febrile seizures can occur anytime a child has a fever, but the typical child who has a febrile seizure quickly and fully recovers."
       
      More information is needed before any science-driven recommendation change can be made, so additional data will continue to be collected and analyzed this season. The AAP believes that ensuring both vaccines are given in a timely fashion outweighs any perceived benefit associated with giving them at separate times.

      Go to Red Book text:
      Section 3, Influenza
      Influenza Resource Page


      August 2011

      ACIP Recommendations for 2011�12 Influenza SeasonPosted 8/23/11
      The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention released updated guidance for the use of influenza vaccines in the United States for the 2011�12 influenza season. Influenza vaccine strains for the 2011�12 season are unchanged from those for the 2010�11 season. Vaccination of all persons 6 months of age and older continues to be recommended as does annual vaccination for those who received the vaccine for the previous season.

      See the full ACIP report for information regarding vaccine strains for the 2011�12 influenza season, the vaccination schedule for children 6 month through 8 years of age, and considerations for vaccination of persons with egg allergy.

      ACIP report
      Go to Red Book text:
      Section 3, Influenza
      Influenza Resource Page

      Red Book Now on Facebook!Posted 8/11/11
      The American Academy of Pediatrics Red Book now has its own page on Facebook. You can see the page at http://www.facebook.com/aapredbook or find it by searching on Facebook for "AAP Red Book."

      Join the Red Book community on Facebook today! A new way to keep track of Red Book informational updates, special events, infectious disease topics, and more.


      July 2011

      Correction to eAlert Message: Approval of New RotaTeq LabelPosted 7/26/11
      Please note a correction to the below message that was sent as a Red Book Online eAlert on Friday, July 22, 2011. The original message stated that the Centers for Disease Control and Prevention approved a new label for RotaTeq, which is incorrect. The message should state that the Food and Drug Administration (FDA) approved the new label for RotaTeq.

      Corrected message:
      The FDA approved a new label for RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent). The new label now contains a contraindication for history of intussusception. In addition, the Prescribing Information and Patient Package Insert were revised.

      Approval Letter
      Prescribing Information

      Go to Red Book text:
      Section 3, Rotavirus Infections

      Approval of New RotaTeq LabelPosted 7/22/11
      The Centers for Disease Control and Prevention approved a new label for RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent). The new label now contains a contraindication for history of intussusception. In addition, the Prescribing Information and Patient Package Insert were revised.

      Approval Letter
      Prescribing Information

      Go to Red Book text:
      Section 3, Rotavirus Infections

      Label Change for Tamiflu for Oral SuspensionPosted 7/20/11
      Tamiflu (oseltamivir phosphate) for oral suspension labels are being changed to reduce the likelihood of prescribing and dosing confusion which can lead to medication errors. These changes include:
      • Concentration change from 12 mg/mL to 6 mg/mL; this lower concentration is less likely to become frothy when shaken, which will allow a more accurate measurement
      • Change in the measurements of the oral dosing device from milligrams to milliliters
      • Change to the dosing table to include a column for the volume (mL) based on the new 6 mg/mL concentration
      • Revised container labels and carton packaging
      • Revised compounding instructions for pharmacies to prepare a 6 mg/mL oral suspension from Tamiflu capsules in an emergency situation only if the commercially manufactured Tamiflu for oral suspension is unavailable
      Genentech, the manufacturer of Tamiflu for oral suspension, has begun distributing the new 6 mg/mL product and instituted a voluntary return program for wholesale buyers, distributors, and pharmacies of the 12 mg/mL product. The 12 mg/mL will remain in the marketplace until current supplies expire.

      Healthcare professionals should be aware that both concentrations of Tamiflu for oral suspension will be on the market during the 2011-2012 influenza season. To avoid potential medication errors, prescribers should include the new concentration (6 mg/mL) and dose in milliliters on all prescriptions for Tamiflu for oral suspension.

      Go to MedWatch for the entire safety alert, including a link to the Drug Safety Communication.

      Go to Red Book text:
      Section 3, Influenza
      Section 4, Antiviral Drugs


      March 2011

      Red Book Online Approved for Internet Point of Care CMEPosted 3/29/11
      Red Book Online recently became an approved source that you can search through the new PediaLink Internet Point of Care Search CME activity.

      Look for the "Earn CME" link on any Red Book Online content page. Click this link to go to the AAP PediaLink Internet Point of Care Search where you can start earning CME credit by following four easy steps:
      1. Identify the clinical question that prompted your information search.
      2. Initiate and store your results from searching content in Red Book Online.
      3. Document the sources that were consulted once the search is complete.
      4. List the expected application to practice in order to claim credit.
      This CME activity is available to all AAP fellows as a free member benefit. If logged in as an individual on Red Book Online, you will automatically be logged in on the PediaLink site after clicking the �Earn CME� link. If you are not logged in as an individual, simply sign in on the PediaLink home page and click the "Internet Point of Care Search" tab in the top navigation.


      February 2011

      U.S. Supreme Court Upholds Vaccine Injury Compensation ProgramPosted 2/22/11
      The U.S. Supreme Court ruled today in Bruesewitz v. Wyeth, Inc. (No. 09-152, S. Ct.) to preserve the Vaccine Injury Compensation Program (VICP) that was established in the National Childhood Vaccine Injury Compensation Act of 1986.

      In a 6-2 decision, the Court upheld a recent ruling by the Third Circuit Court and supported the Academy�s position in the case, stating "The National Childhood Vaccine Injury Act preempts all design-defect claims against vaccine manufacturers brought by plaintiffs who seek compensation for injury or death caused by vaccine side effects." Justice Breyer issued a concurring opinion citing the Academy�s support for the retention of vaccine manufacturer tort liability.

      For a link to the amici curiae brief filed by AAP in the case in 2010, and a link to the full decision of the Supreme Court (including Justice Breyer�s opinion), please see the statement issued by the AAP on the February 22, 2011 decision.

      Go to Red Book text:
      Section 1, Vaccine Safety and Contraindications
      Section 1, Reporting of Adverse Events

      PCR Testing for Pertussis � Best PracticesPosted 2/18/11
      Due to the continuing pertussis resurgence, the Centers for Disease Control and Prevention (CDC) Health Alert Network (HAN) sent out a message on February 16, 2011 providing best practices for health care professionals on using polymerase chain reaction (PCR) tests for diagnosing pertussis. The best practices include who and when to test; how to obtain specimens; and how do to avoid contamination of clinical specimens with pertussis DNA, including best practices for preparing and administering vaccines and adhering to basic infection-control measures. Also included are recommendations for understanding and interpreting PCR results.

      Visit the CDC web site to view the best practices for using PCR tests to diagnose pertussis.

      CDC web site
      Go to Red Book text:
      Section 3, Pertussis (Whooping Cough)


    January 2011

    Recommended Changes for Tdap Vaccine UsePosted 1/11/11
    The American Academy of Pediatrics Committee on Infectious Diseases approved the following changes for the use of tetanus toxoid, reduced content diphtheria toxoid and pertussis antigen (Tdap) vaccine in children and adults that were recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.
    • Removal of a minimum interval between receipt of a tetanus- or diphtheria-toxoid-containing vaccine and Tdap when Tdap is otherwise indicated;
    • Administration of a single dose of Tdap to children 7 through 10 years of age with incomplete or unknown pertussis vaccine history;
    • Administration of a single dose of Tdap to persons 65 years of age or older who have or anticipate having close contact with an infant younger than 12 months of age (e.g., grandparents, child care providers, health care workers); and
    • Permission to administer a single dose of Tdap in place of Td to any person 65 years of age or older who has not received Tdap previously.
    For additional information on these new recommendations, please see the article published in the January edition of AAP News.

    Go to Red Book text:
    Section 3, Tetanus (Lockjaw)
    Section 3, Diphtheria
    Section 3, Pertussis (Whooping Cough)

    New Recommendations for MCV4 UsePosted 1/6/11
    The American Academy of Pediatrics Committee on Infectious Diseases approved the two new modifications for the use of quadrivalent meningococcal vaccines (MCV4, Menactra, and Menveo) recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention. These new recommendations will affect the 2011 immunization schedule.

    The first recommendation is the addition of a second dose (at least two months apart from the first) of MCV4 for immunocompromised children (complement deficiency, asplenia, HIV infection).

    The second recommendation is the addition of a routine booster of MCV4 for adolescents at 16 years of age (i.e., vaccinate at 11 through 12 years followed by a booster at 16 years).

    For additional information on these new recommendations, please see the article published in the January edition of AAP News.

    Go to Red Book text:
    Section 3, Meningococcal Infections